Sara A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center

Sara A. Hurvitz, MD, reviews therapy options for patients with HER2-positive metastatic breast cancer and comments on emerging therapeutic strategies.

Sara A. Hurvitz, MD, comments on her preferences for treating patients with HER2-positive metastatic breast cancer and shares her strategy for sequencing therapies.

Recommendations for mitigating and managing common treatment-related adverse events associated with tucatinib, trastuzumab, and capecitabine based on safety data from HER2CLIMB.

Combination therapy with tucatinib, trastuzumab, and capecitabine shows efficacy in all patient populations studied.

Efficacy of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer, including patients with brain metastases or visceral disease.

An overview of treatment options for HER2-positive metastatic breast cancer and practical guidance on selecting therapy.